[{"id":"37fa384b-e7a2-4ce7-847c-4eaff8ded1d9","acronym":"SPRINT 2","url":"https://clinicaltrials.gov/study/NCT07146230","created_at":"2025-08-30T13:48:56.537Z","updated_at":"2025-08-30T13:48:56.537Z","phase":"Phase 2","brief_title":"The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2","source_id_and_acronym":"NCT07146230 - SPRINT 2","lead_sponsor":"Montefiore Medical Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-08-28"},{"id":"57bae4b0-28a5-4fa9-adc4-a7b4d7841588","acronym":"NeoCOAST-2","url":"https://clinicaltrials.gov/study/NCT05061550","created_at":"2021-09-29T11:53:57.404Z","updated_at":"2025-02-25T15:12:20.063Z","phase":"Phase 2","brief_title":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05061550 - NeoCOAST-2","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • Datroway (datopotamab deruxtecan-dlnk) • oleclumab (MEDI9447) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • falbikitug (AZD0171) • monalizumab (IPH2201)"],"overall_status":"Recruiting","enrollment":" Enrollment 630","initiation":"Initiation: 04/14/2022","start_date":" 04/14/2022","primary_txt":" Primary completion: 05/09/2030","primary_completion_date":" 05/09/2030","study_txt":" Completion: 05/09/2030","study_completion_date":" 05/09/2030","last_update_posted":"2025-02-13"},{"id":"3ec23c8c-cbf9-4200-8659-8f1562c5185d","acronym":"PACIFIC-9","url":"https://clinicaltrials.gov/study/NCT05221840","created_at":"2022-02-05T18:29:09.587Z","updated_at":"2025-02-25T16:38:50.332Z","phase":"Phase 3","brief_title":"A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05221840 - PACIFIC-9","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)"],"overall_status":"Recruiting","enrollment":" Enrollment 999","initiation":"Initiation: 02/07/2022","start_date":" 02/07/2022","primary_txt":" Primary completion: 05/29/2026","primary_completion_date":" 05/29/2026","study_txt":" Completion: 05/31/2030","study_completion_date":" 05/31/2030","last_update_posted":"2025-02-07"},{"id":"e4fc459d-b068-4a6e-bfae-9e69ad869dac","acronym":"","url":"https://clinicaltrials.gov/study/NCT02671435","created_at":"2023-03-09T19:01:21.835Z","updated_at":"2025-02-25T17:29:20.785Z","phase":"Phase 1/2","brief_title":"A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors","source_id_and_acronym":"NCT02671435","lead_sponsor":"MedImmune LLC","biomarkers":" BRAF","pipe":" | ","alterations":" PD-L1 expression","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • Imfinzi (durvalumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • monalizumab (IPH2201)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 383","initiation":"Initiation: 02/22/2016","start_date":" 02/22/2016","primary_txt":" Primary completion: 10/26/2021","primary_completion_date":" 10/26/2021","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-01-30"},{"id":"a3631292-f89e-49a5-a42a-6dcaf6d98ccf","acronym":"MIMOSA","url":"https://clinicaltrials.gov/study/NCT04307329","created_at":"2021-01-18T20:53:12.013Z","updated_at":"2025-02-25T14:58:57.652Z","phase":"Phase 2","brief_title":"Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial","source_id_and_acronym":"NCT04307329 - MIMOSA","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • monalizumab (IPH2201)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 03/23/2021","start_date":" 03/23/2021","primary_txt":" Primary completion: 01/19/2023","primary_completion_date":" 01/19/2023","study_txt":" Completion: 03/23/2024","study_completion_date":" 03/23/2024","last_update_posted":"2024-10-22"},{"id":"aa0bda28-21b1-44ee-bd83-6ab69706eeb9","acronym":"ARCHON-1","url":"https://clinicaltrials.gov/study/NCT03801902","created_at":"2021-01-18T18:47:37.181Z","updated_at":"2024-07-02T16:35:02.360Z","phase":"Phase 1","brief_title":"Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial","source_id_and_acronym":"NCT03801902 - ARCHON-1","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 10/28/2019","start_date":" 10/28/2019","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-05-21"},{"id":"059c44d0-f5a3-4e0a-b39e-6b8103e251ad","acronym":"PIONeeR","url":"https://clinicaltrials.gov/study/NCT03833440","created_at":"2021-01-18T18:55:39.473Z","updated_at":"2024-07-02T16:35:06.100Z","phase":"Phase 2","brief_title":"Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance","source_id_and_acronym":"NCT03833440 - PIONeeR","lead_sponsor":"Assistance Publique Hopitaux De Marseille","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • ROS1 rearrangement","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • docetaxel • Orpathys (savolitinib) • ceralasertib (AZD6738) • oleclumab (MEDI9447) • monalizumab (IPH2201)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 10/08/2019","start_date":" 10/08/2019","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-03"},{"id":"c3005ef7-71ae-4128-b1ae-282cc4e68429","acronym":"IMMUNONCOVID","url":"https://clinicaltrials.gov/study/NCT04333914","created_at":"2021-01-18T20:59:05.040Z","updated_at":"2024-07-02T16:36:03.152Z","phase":"Phase 2","brief_title":"Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection","source_id_and_acronym":"NCT04333914 - IMMUNONCOVID","lead_sponsor":"Centre Leon Berard","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e avdoralimab (IPH5401) • ezurpimtrostat (GNS561) • monalizumab (IPH2201)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/15/2020","start_date":" 04/15/2020","primary_txt":" Primary completion: 07/06/2021","primary_completion_date":" 07/06/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2022-09-30"}]